Cargando…

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis

The structural basis of the antifracture efficacy of strontium ranelate and alendronate is incompletely understood. We compared the effects of strontium ranelate and alendronate on distal tibia microstructure over 2 years using HR-pQCT. In this pre-planned, interim, intention-to-treat analysis at 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzoli, René, Laroche, Michel, Krieg, Marc-Antoine, Frieling, Isolde, Thomas, Thierry, Delmas, Pierre, Felsenberg, Dieter
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908746/
https://www.ncbi.nlm.nih.gov/pubmed/20512336
http://dx.doi.org/10.1007/s00296-010-1542-y
_version_ 1782184228168925184
author Rizzoli, René
Laroche, Michel
Krieg, Marc-Antoine
Frieling, Isolde
Thomas, Thierry
Delmas, Pierre
Felsenberg, Dieter
author_facet Rizzoli, René
Laroche, Michel
Krieg, Marc-Antoine
Frieling, Isolde
Thomas, Thierry
Delmas, Pierre
Felsenberg, Dieter
author_sort Rizzoli, René
collection PubMed
description The structural basis of the antifracture efficacy of strontium ranelate and alendronate is incompletely understood. We compared the effects of strontium ranelate and alendronate on distal tibia microstructure over 2 years using HR-pQCT. In this pre-planned, interim, intention-to-treat analysis at 12 months, 88 osteoporotic postmenopausal women (mean age 63.7 ± 7.4) were randomized to strontium ranelate 2 g/day or alendronate 70 mg/week in a double-placebo design. Primary endpoints were changes in microstructure. Secondary endpoints included lumbar and hip areal bone mineral density (aBMD), and bone turnover markers. This trial is registered with http://www.controlled-trials.com, number ISRCTN82719233. Baseline characteristics of the two groups were similar. Treatment with strontium ranelate was associated with increases in mean cortical thickness (CTh, 5.3%), cortical area (4.9%) and trabecular density (2.1%) (all P < 0.001, except cortical area P = 0.013). No significant changes were observed with alendronate. Between-group differences in favor of strontium ranelate were observed for CTh, cortical area, BV/TV and trabecular density (P = 0.045, 0.041, 0.048 and 0.035, respectively). aBMD increased to a similar extent with strontium ranelate and alendronate at the spine (5.7% versus 5.1%, respectively) and total hip (3.3% versus 2.2%, respectively). No significant changes were observed in remodeling markers with strontium ranelate, while suppression was observed with alendronate. Within the methodological constraints of HR-pQCT through its possible sensitivity to X-ray attenuation of different minerals, strontium ranelate had greater effects than alendronate on distal tibia cortical thickness and trabecular volumetric density.
format Text
id pubmed-2908746
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-29087462010-08-06 Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis Rizzoli, René Laroche, Michel Krieg, Marc-Antoine Frieling, Isolde Thomas, Thierry Delmas, Pierre Felsenberg, Dieter Rheumatol Int Original Article The structural basis of the antifracture efficacy of strontium ranelate and alendronate is incompletely understood. We compared the effects of strontium ranelate and alendronate on distal tibia microstructure over 2 years using HR-pQCT. In this pre-planned, interim, intention-to-treat analysis at 12 months, 88 osteoporotic postmenopausal women (mean age 63.7 ± 7.4) were randomized to strontium ranelate 2 g/day or alendronate 70 mg/week in a double-placebo design. Primary endpoints were changes in microstructure. Secondary endpoints included lumbar and hip areal bone mineral density (aBMD), and bone turnover markers. This trial is registered with http://www.controlled-trials.com, number ISRCTN82719233. Baseline characteristics of the two groups were similar. Treatment with strontium ranelate was associated with increases in mean cortical thickness (CTh, 5.3%), cortical area (4.9%) and trabecular density (2.1%) (all P < 0.001, except cortical area P = 0.013). No significant changes were observed with alendronate. Between-group differences in favor of strontium ranelate were observed for CTh, cortical area, BV/TV and trabecular density (P = 0.045, 0.041, 0.048 and 0.035, respectively). aBMD increased to a similar extent with strontium ranelate and alendronate at the spine (5.7% versus 5.1%, respectively) and total hip (3.3% versus 2.2%, respectively). No significant changes were observed in remodeling markers with strontium ranelate, while suppression was observed with alendronate. Within the methodological constraints of HR-pQCT through its possible sensitivity to X-ray attenuation of different minerals, strontium ranelate had greater effects than alendronate on distal tibia cortical thickness and trabecular volumetric density. Springer-Verlag 2010-05-29 2010 /pmc/articles/PMC2908746/ /pubmed/20512336 http://dx.doi.org/10.1007/s00296-010-1542-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Rizzoli, René
Laroche, Michel
Krieg, Marc-Antoine
Frieling, Isolde
Thomas, Thierry
Delmas, Pierre
Felsenberg, Dieter
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title_full Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title_fullStr Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title_full_unstemmed Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title_short Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
title_sort strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908746/
https://www.ncbi.nlm.nih.gov/pubmed/20512336
http://dx.doi.org/10.1007/s00296-010-1542-y
work_keys_str_mv AT rizzolirene strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT larochemichel strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT kriegmarcantoine strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT frielingisolde strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT thomasthierry strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT delmaspierre strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis
AT felsenbergdieter strontiumranelateandalendronatehavedifferingeffectsondistaltibiabonemicrostructureinwomenwithosteoporosis